David H Stern

US Patent:

6391300, May 21, 2002

Filed:

Nov 16, 1998

Appl. No.:

09/192905

Inventors:

Eric Rose - Tenafly NJ
David Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Talia Spanier - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3836

US Classification:

4241451, 424 9464, 4241581, 435226, 514 2, 514 12, 530381

Abstract:

This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0. 1 g/ml plasma to about 250 g/ml plasma or from about 0. 5 g/ml plasma to about 25 g/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient.

US Patent:

6465422, Oct 15, 2002

Filed:

Apr 17, 1998

Appl. No.:

09/062365

Inventors:

Ann Marie Schmidt - Franklin Lakes NJ
David Stern - Great Neck NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A21K 3718

US Classification:

514 2, 4241844, 4241851, 4241921, 435 691, 4353201, 435325, 530350, 530351, 530380, 536 231, 536 235, 536 234

Abstract:

The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.

US Patent:

6555340, Apr 29, 2003

Filed:

Mar 5, 1999

Appl. No.:

09/263312

Inventors:

Ann Marie Schmidt - Franklin Lakes NJ
David Stern - Great Neck NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C12P 2106

US Classification:

435 691, 4353201, 435325, 536 235

Abstract:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

US Patent:

6555651, Apr 29, 2003

Filed:

Oct 9, 1997

Appl. No.:

08/948131

Inventors:

David Stern - Great Neck NY
Shi Du Yan - New York NY
Ann Marie Schmidt - Franklin Lakes NJ
Ira Lamster - Wyckoff NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3800

US Classification:

530324, 530300

Abstract:

The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (SEQ. ID No: 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid- peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid- peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid- peptide with the receptor for advanced glycation endproduct.

US Patent:

6563015, May 13, 2003

Filed:

Aug 14, 2000

Appl. No.:

09/638649

Inventors:

David M. Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Shi Du Yan - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 3300

US Classification:

800 3, 800 12, 800 18

Abstract:

The invention provides for a non-human transgenic animal whose cells contain a recombinant DNA sequence comprising: (a) a nerve tissue specific promoter operatively linked to a DNA sequence which encodes human receptor for advanced glycation endproducts (RAGE), and (b) a nerve tissue specific promoter operatively linked to a DNA sequence encoding a mutant human amyloid precursor protein hAPP695, hAPP751 and hAPP770 bearing mutations linked to familial Alzheimers disease in humans, wherein said non-human transgenic animal exhibits at least one phenotype from the group consisting of: increased expression of M-CSF gene in cerebral cortex; increased expression of IL-6 gene in cerebral cortex; increased neuronal stress; increased neurotoxicity; neuron loss; increased level of activated form of caspase 3 in brain; and increased level of phosphorylated tau protein in brain.

US Patent:

6576582, Jun 10, 2003

Filed:

Nov 15, 1995

Appl. No.:

08/558309

Inventors:

Jeffrey S. Beck - Lawrenceville NJ
Jane C. Cheng - Clarksburg NJ
Sharon B. McCullen - Newtown PA
David H. Olson - Pennington NJ
David L. Stern - Lawrenceville NJ

Assignee:

ExxonMobil Oil Corporation - Fairfax VA

International Classification:

B01J 2906

US Classification:

502 71, 502 63, 502 64, 502 77, 502 85

Abstract:

There is provided a substantially binder-free catalytic molecular sieve which has been modified by being ex situ selectivated with a silicon compound. The ex situ selectivation involves exposing the molecular sieve to at least two silicon impregnation sequences, each sequence comprising an impregnation with a silicon compound followed by calcination. The catalyst may be used in a hydrocarbon conversion process, such as toluene disproportionation.

US Patent:

6610264, Aug 26, 2003

Filed:

May 5, 1995

Appl. No.:

08/435920

Inventors:

John Scott Buchanan - Trenton NJ
David L. Stern - Lawrenceville NJ
Gerald J. Teitman - Vienna VA

Assignee:

ExxonMobil Oil Corporation - Fairfax VA

International Classification:

B01D 5348

US Classification:

4232421, 423222, 42324401, 42324402, 42324406, 42324407, 4235731, 4235741, 4235768

Abstract:

A process and system is disclosed for removing sulfur from tail-gas emitted from a Claus sulfur recovery process. First, the tail-gas is oxidized so as to convert sulfur therein to sulfur oxides. Oxidized tail-gas is directed into an absorber where a solid absorbent absorbs substantially all the sulfur oxides thereon. After allowing sufficient time for a desired amount of sulfur oxides to be absorbed, absorption is ceased. Next, the solid absorbent containing the absorbed sulfur oxides is contacted with a reducing gas so as to release an off gas containing hydrogen sulfide and sulfur dioxide. Upon releasing sulfur from the solid absorbent, the solid absorbent is regenerated and redirected into the absorber. Sulfur in the off gas emitted by regeneration is concentrated to an extent sufficient for use within a Claus sulfur recovery process for conversion to elemental sulfur. By combining this process with a Claus sulfur recovery process, sulfur dioxide emissions can be reduced to less than about two parts per million.

US Patent:

6670136, Dec 30, 2003

Filed:

Apr 5, 2001

Appl. No.:

09/826589

Inventors:

Ann Marie Schmidt - Franklin Lakes NJ
David Stern - Great Neck NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 3353

US Classification:

435 71, 530324, 530350, 5303881, 5303891

Abstract:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a)(i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.